Answers are grounded in this paper and cite their sources.
Randomized trials evaluate BCMA-directed therapies in early relapse multiple myeloma, suggesting new treatment options.
The treatment landscape for multiple myeloma is evolving rapidly with the integration of novel BCMA-directed therapies. In the early relapse setting (1-3 prior lines of therapy), several practice-changing phase 3 trials have reported results in the past two years, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates. These studies offer exciting new options for clinicians but also introduce complexity due to differences in patient populations, trial designs, and real-world applicability. We synthesize the data from trials exploring BCMA-directed immunotherapy in early relapse setting, explore nuances in trial characteristics and their implications for treatment selection, and discuss treatment decision determinants, including age, fitness, comorbidities, treatment exposure and access. We subsequently discuss how emerging BCMA-directed therapy affects decision making in several common scenarios. For each of these common scenarios we explore applicability and limitation from the clinical trials, treatment access and logistical considerations and importance of shared decision-making.
No takes yet. Share an insight, caveat, or question.
Hansen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: